Torgyn Duo

Quick links to important sections

Torgyn Duo

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Torgyn Duo

Quick Facts

Property Description
Active ingredients Clindamycin Phosphate, Ketoconazole
Form Vaginal ovule (soft capsule)
Pharmacological class Antimicrobial and Antifungal Agent
Common purpose Localized treatment of mixed infections
Origin Synthetic combination product

What Type of Medicine is Torgyn Duo?

Torgyn Duo is a fixed-dose combination medicinal preparation classified as an Antimicrobial and Antifungal Agent designed for highly localized treatment. This prescription-only product, manufactured in the form of a soft vaginal ovule, represents a strategic design to address both bacterial and fungal components often involved in mixed localized infections, commonly targeting adult women. This distinguishes it from single-agent therapies by delivering two different therapeutic compounds in a single unit, a strategy recognized for providing broad-spectrum coverage in gynaecological infections.

Composition and Form: Clindamycin and Ketoconazole Ovules

The unique action of the Torgyn Duo formulation is derived from its two active ingredients: Clindamycin Phosphate and Ketoconazole. Clindamycin is classified as a semi-synthetic Lincosamide antibiotic, and Ketoconazole belongs to the Imidazole antifungal class of medications. Combining agents like a Lincosamide antibiotic and an azole antifungal is a recognized approach for providing comprehensive coverage in local treatment. The final dosage form is a soft vaginal ovule or capsule, enabling the medicine to be administered via the topical intravaginal route and ensuring high concentration of the synthetic compounds directly at the affected site.

General Purpose of the Dual-Action Formula

The general purpose of this dual-action formula is to provide simultaneous, focused coverage against a broad range of susceptible pathogens in a localized context. Clindamycin works by inhibiting protein synthesis in bacteria, and Ketoconazole disrupts the integrity of fungal cell membranes. This strategic combination aims to leverage a synergistic effect, offering a streamlined treatment approach to simplify the management of mixed localized infections without requiring the separate application of two different medicines.

Regulatory References

  1. Ketoconazole - LiverTox - NIH

What side effects are possible with Torgyn Duo?

Adverse Reaction Scope

Category Description (Based on Regulatory Documents)
Key adverse reaction categories Localized effects at the application site (vaginal irritation, burning, pruritus), and systemic effects including gastrointestinal disturbances, headache, and dermatological reactions.
Frequency classification Primarily categorized as Common (e.g., local irritation, headache) and Uncommon/Not Known (e.g., severe hypersensitivity reactions, Pseudomembranous Colitis).
System-organ classes involved Gastrointestinal Disorders, Reproductive System and Breast Disorders (local effects), Nervous System Disorders, and Immune System Disorders.
Serious adverse reactions Pseudomembranous Colitis (associated with the clindamycin component), and severe immunological reactions like Anaphylaxis are documented in official safety information.
Population-specific safety considerations Contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Caution is advised regarding use during the first trimester of pregnancy.
Safety-related restrictions or limitations The ovule's excipient base may weaken latex or rubber products (e.g., condoms, diaphragms); use of such products is restricted during and for a specified time period following treatment.

Resulting Safety Structure

  • Common localized effects at the application site (e.g., irritation, burning) are the most frequently noted safety characteristics.
  • Systemic safety concerns focus on the potential for gastrointestinal effects, including the documented, rare but serious risk of Pseudomembranous Colitis.
  • Safety constraints strictly prohibit use in patients with certain pre-existing bowel diseases and detail the restriction on co-use with latex barrier contraceptives.

Connection to the Overall Safety Profile

The official safety information structures the understanding of risks by emphasizing that the most common concerns are localized, temporary effects related to the application route. However, the profile is formally constrained by the documented, rare but serious risk of antibiotic-associated gastrointestinal pathology and by specific cautions regarding use in the first trimester of pregnancy and in patients with a history of inflammatory bowel conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses overdose primarily in the context of accidental oral ingestion, as the risk of systemic toxicity is generally considered low following recommended local administration.

Documented Overdose Manifestations

In the event of acute, excessive systemic exposure, the resulting signs and symptoms are expected to mirror those of the individual active components, Clindamycin and Ketoconazole. These may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. More severe outcomes associated with the components’ known toxicological profiles may involve hepatic (liver) effects from Ketoconazole and, rarely, neuromuscular effects from Clindamycin at high systemic doses.

Immediate Actions and Management

Immediate medical attention must be sought if the product is accidentally ingested or if any signs of severe systemic reactions or toxicity are observed following excessive use.

Treatment of overdose is generally symptomatic and supportive. Standard procedures include establishing and maintaining essential supportive measures for vital functions. Management may also involve specific measures to reduce drug absorption, such as the administration of activated charcoal, as deemed appropriate by a medical professional. As a principle of management, observation is required until the patient’s condition is stable and systemic effects have been managed.

Therapeutic Uses of Torgyn Duo

What Torgyn Duo Treats: Main Uses and Benefits

Primary Treatment for Mixed Bacterial and Fungal Vaginitis

The combination medicine is applied in clinical settings marked by mixed gynecological infections, primarily the simultaneous presence of Bacterial Vaginosis (BV) and Vaginal Candidiasis. This therapeutic approach is used for managing these dual etiologies. It is commonly used when symptoms are driven by a polymicrobial imbalance, offering a single therapeutic intervention to address both common infectious causes. The treatment provides support that contributes to easing the overall symptom load.


Symptomatic Relief from Abnormal Discharge and Discomfort

Torgyn Duo is applied in addressing symptom clusters that may become intense or disruptive, which commonly include abnormal vaginal discharge, malodor, and localized symptoms like itching (pruritus) and burning. The support is relevant for managing symptoms that interfere with daily comfort. The support helps maintain a sense of stability when symptoms are more noticeable. The medicine is commonly used across conditions presenting with acute episodes, and may assist with easing the symptom load associated with inflammatory or irritative states.


Quick Fact: Supportive Symptom Management
May assist with easing the symptom load, including itching, burning, and malodor, in cases of mixed vaginitis.

Eligibility and Restrictions for Use

The eligibility for Torgyn Duo is strictly defined by regulatory documents, which establish specific populations for whom use is permitted, restricted, or prohibited.

Contraindications and Prohibitions

The medicine is contraindicated and must not be used by individuals with a history of hypersensitivity or allergy to Clindamycin, Ketoconazole, Lincomycin, or any components of the ovule. Use is also strictly prohibited for patients with a history of inflammatory bowel conditions, including regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Age and Physiological Restrictions

Use is officially established for post-menarchal females, encompassing adult and adolescent women. Safety and efficacy have not been established in pre-menarchal females (children). Use during pregnancy is conditional, meaning it should be administered only if the medical benefit is considered by a physician to clearly outweigh the potential risks. Similarly, use while breastfeeding is conditional.

Population Status Regulatory Classification
History of Colitis Contraindicated (Prohibited)
Pre-Menarchal Females Use Not Established
Pregnancy / Lactation Conditional Use (Risk-Benefit Assessment)

Caution is advised by some regulatory authorities when Torgyn Duo is used by patients with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Torgyn Duo, a combination product containing metronidazole and miconazole, are primarily driven by the systemic absorption of metronidazole and local effects within the vagina. Patients should be informed of specific restrictions and combinations that require caution.


Contraindicated and Restricted Combinations

  • Alcohol: Consumption of alcoholic beverages or products containing alcohol is strictly discouraged during treatment and for a minimum of one day, and often up to three days, following the final dose. This is due to the metronidazole component, which can lead to a disulfiram-like reaction. Symptoms may include flushing, headache, nausea, vomiting, and abdominal cramps.
  • Vaginal Products: Simultaneous use of other products intended for vaginal administration, such as spermicides or vaginal douches, is not recommended. This restriction is to prevent potential inactivation of the product's therapeutic effect and to avoid possible damage to contraceptive barrier devices like condoms and diaphragms, as the suppository base may react with their rubber components.

Caution with Systemic Medicines

  • Enzyme Inducers: Medicines that are strong inducers of hepatic enzymes, particularly those affecting the CYP3A4 system, may accelerate the metabolism of metronidazole. This action can lead to decreased plasma concentrations of metronidazole, potentially reducing its therapeutic effectiveness. Examples of such enzyme-inducing agents include phenytoin and phenobarbital.
  • Oral Anticoagulants (Warfarin): Due to the miconazole component, which may inhibit certain metabolic enzymes (CYP2C9), there is a potential for an enhanced anticoagulant effect with medicines like warfarin. This combination requires close monitoring of the International Normalized Ratio (INR) and prothrombin time to mitigate the risk of bleeding.

Mechanism of Action

Mechanism of Action: Inhibiting Bacterial Growth

The Clindamycin component targets the core synthetic machinery of susceptible bacteria. It functions as an inhibitor by binding specifically and reversibly to the 50S ribosomal subunit, blocking the peptidyl transferase center and preventing bacteria from forming essential proteins. This action arrests cell growth and replication, resulting in a physiological consequence of limiting the multiplication of susceptible bacteria at the site of application.


Mechanism of Action: Fungal Membrane Disruption

The Ketoconazole component acts by inhibiting the fungal enzyme Cytochrome P450 14alpha-demethylase (CYP51A1). This blockade disrupts the crucial ergosterol biosynthesis pathway, which leads to the depletion of ergosterol—a vital structural lipid. This molecular sequence results in the structural failure and increased permeability of the fungal cell membrane, leading to disruption of cellular viability.


Synergy Through Complementary Suppression

The drug operates through two distinct and parallel mechanistic domains, delivering a simultaneous dual-mechanism suppression. This dual targeting of the bacterial ribosome and the fungal sterol pathway provides a combined physiological approach for modulating mixed microbial populations. This approach enables high-concentration molecular engagement against two distinct pathogen classes.

Dosage and Administration Information

How to Use Torgyn Duo

The administration of Torgyn Duo is based on a fixed-course, topical protocol for this fixed-dose combination of Clindamycin and Ketoconazole. The high-level usage principles structure the general pattern of how the medicine is applied in clinical practice, focusing on the route, frequency, duration, and contextual timing.


Official Administration Guidelines

Field Instruction
Route of administration The medicine is delivered via the Intravaginal route (Topical application).
Dosing schedule The standard regimen is one ovule (fixed-dose combination) per single administration. A dosage strength consists of Clindamycin 100 mg and Ketoconazole 800 mg per ovule.
Frequency The ovule is administered once daily.
Course duration The treatment is structured as a short, fixed course, typically spanning three consecutive days.
Age-group rules The standard regimen is established for use in adult women (post-menarche).

Contextual Usage Principles

The ovule is generally recommended for administration at bedtime to maximize the localized contact time of the active ingredients with the vaginal tissue and promote retention. The fixed-dose, single-unit administration is designed to deliver both the antibiotic and antifungal agents simultaneously.

The excipient base of the formulation necessitates a temporary restriction on the use of certain latex or rubber products (such as condoms or diaphragms) during the course of treatment due to potential material degradation. This constraint is part of the procedural instructions tied to the proper use of the medicine.

Recent Clinical Evidence

Overview of Research Evidence for Torgyn Duo

Evidence for Use in Mixed Bacterial and Fungal Vaginitis

The combination product was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations, specifically when both bacterial and fungal components are present, a condition commonly known as mixed vaginitis. The research primarily examined the dual-agent ovule in Randomized Controlled Trials (RCTs) and comparative studies, which often included comparisons to other pharmacological options. These studies monitored patient-reported outcomes describing perceived discomfort, including reports of burning, itching, and abnormal discharge, which are key outcomes reflecting daily functioning or activity level. Research explored how symptoms change over time across the observed patient groups.


Types of Studies and Measured Outcomes

The available research base was evaluated in designs that explore both Clinical Endpoints and Microbiological Endpoints. Clinical Endpoints were observed in studies relevant in trials assessing short-term or episodic symptom patterns. For example, trials reported measurements of symptom resolution and the quality of discharge over a set period. Microbiological Endpoints involved follow-up testing to monitor the status of target pathogens, such as Candida albicans and key bacteria associated with the studied condition. In studies assessing this combination, findings describe patterns observed in the studies where measurements of pathogen status were reported in patients with candidiasis and mixed infections. The evidence contributes to understanding symptom patterns and how these infections are measured in research settings.


Research Gaps and Areas of Uncertainty

The majority of the core evidence is relevant in trials assessing short-term or episodic symptom patterns, with primary assessments of resolution typically occurring 7 to 11 days after the beginning of treatment. Symptom status and changes were evaluated in these defined time intervals. One limitation is that follow-up durations were limited for assessing recurrence patterns, which means long-term effects are not fully established. Additionally, data for certain groups remain insufficient, such as pregnant or nursing women. Findings describe group patterns, not personal outcomes, and research does not provide individual predictions of response.

Key Studies & References

  1. Comparison of efficacy of combination of ketokonazol 400 mg + clindamycin 100 mg with ketokonazol 800 mg + clindamycin 100 mg in the treatment of vaginitis due to Candida and bacterial vaginosis
  2. NCT00889356: Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis

Frequently Asked Questions (FAQ)

Common questions about Torgyn Duo (FAQ)


Q: How quickly does Torgyn Duo usually start working after taking it?

A: Clinical studies show that the time it takes to feel symptom relief can vary among individuals. While the ovule begins releasing its active ingredients immediately upon administration, clinical trials commonly assess the resolution of key symptoms, such as discharge, itching, and burning, within 7 to 11 days after the start of the short treatment course.


Q: Is it common to feel a little dizzy when you first start taking Torgyn Duo?

A: Dizziness has been reported as a possible side effect with this class of topical medication, according to regulatory safety documents. Other effects on the nervous system, such as headache, are more commonly reported. Patients experiencing new or bothersome side effects are advised to consult their healthcare provider.


Q: Do people usually take Torgyn Duo for short-term pain or for a long time?

A: Torgyn Duo is designed as a short, fixed-course treatment for infection, typically spanning only three consecutive days. Official administration guidelines describe it as a short-course treatment, not one for long-term use. It is an anti-infective treatment and is not indicated for treating general or long-term pain.


Q: How long does the effect of one dose of Torgyn Duo typically last?

A: The ovule is administered once daily, usually at bedtime, suggesting the formulation provides adequate localized therapeutic concentration to cover a 24-hour period. Pharmacokinetic data indicates the clindamycin component has a mean elimination half-life of approximately 11 hours following intravaginal administration.


Q: Does Torgyn Duo cause weight gain or affect my appetite?

A: Weight gain is not commonly listed as an adverse reaction in the available safety information for similar topical products. Loss of appetite (anorexia) has been reported with systemic use of clindamycin, but this is less relevant to the topical ovule due to minimal systemic absorption.


Q: What happens if I forget to take a dose of Torgyn Duo?

A: Official instructions for a forgotten dose typically guide patients to apply it when remembered, unless it is close to the next scheduled dose. If it is almost time for the next dose, the missed one is usually skipped. The guidance also advises against doubling up doses.


Q: Is it safe for older people, like those over 65, to use Torgyn Duo?

A: Regulatory documents state that appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of similar products in older adults. The medicine is established for use in adult women generally. Individual concerns regarding use in the elderly population are best reviewed with a healthcare provider.


Q: Can Torgyn Duo be taken with common over-the-counter pain relievers like paracetamol?

A: Drug interaction information generally focuses on systemic medications with known, high-risk interactions, such as blood thinners (warfarin) or strong enzyme inducers. Interactions with non-prescription pain relievers like paracetamol are not typically detailed, and questions regarding co-administration with non-prescription medicines are best addressed by consulting a healthcare professional.


Q: Are there any known interactions between Torgyn Duo and herbal supplements like St. John's Wort?

A: The medicine is known to interact with strong enzyme-inducing medicines that affect the CYP3A4 system, which could potentially reduce the effectiveness of one of the active ingredients. Patients should ensure their healthcare provider is aware of all herbal supplements being taken, particularly those known to be enzyme inducers like St. John's Wort.


Q: Is Torgyn Duo available in different forms, like liquid or extended-release?

A: According to the official product information, Torgyn Duo is only available as a soft vaginal ovule (capsule) for localized intravaginal use. It is not manufactured or intended for use in oral, liquid, or extended-release forms.


Q: Are there any common skin reactions associated with taking Torgyn Duo?

A: The most common localized reactions reported at the application site include itching (pruritus) and redness or irritation (erythema). Generalized mild skin rashes have also been reported in association with the clindamycin component of the medicine.


Q: Can Torgyn Duo be crushed or split if someone has trouble swallowing pills?

A: The Torgyn Duo ovule is specifically designed for intravaginal application and is not a pill meant for oral use. The ovule is designed for intravaginal application and should not be crushed, chewed, or swallowed. It is to be applied intact, as specified in the product's administration guidelines.


Q: Does Torgyn Duo affect kidney or liver function in healthy people?

A: Caution is advised in regulatory documents for patients who already have severe hepatic (liver) or renal (kidney) impairment. Due to the minimal systemic absorption of the topical ovule, significant effects on the kidney or liver function of otherwise healthy individuals are considered less likely than with high-dose oral or intravenous use.


Q: Is Torgyn Duo effective for all types of inflammatory conditions?

A: No. Torgyn Duo is indicated only for the localized treatment of mixed infections involving both bacterial and fungal pathogens in the vagina. It is not approved or intended for use in all types of inflammatory conditions throughout the body.


Q: Why is Torgyn Duo sometimes prescribed for conditions that aren't purely inflammatory?

A: The primary indication for Torgyn Duo is to treat infections, specifically those involving a mix of bacterial and fungal pathogens, rather than treating inflammation alone. The active ingredients function primarily as an antimicrobial (Clindamycin) and an antifungal agent (Ketoconazole).


Q: How soon after stopping Torgyn Duo is it completely out of my system?

A: Systemic absorption of the ingredients from the ovule is low. The mean apparent elimination half-life for the clindamycin component has been reported to be approximately 11 hours, meaning the amount of medicine absorbed into the bloodstream gradually decreases over the following days.


Q: What are the less common, but possible, side effects of Torgyn Duo?

A: Official safety information documents less common but serious risks, which include severe immunological reactions like anaphylaxis (a severe allergic reaction) and the serious risk of Pseudomembranous Colitis (a severe bowel condition). Other uncommon effects are listed in the full safety documentation.


Q: Is Torgyn Duo safe for teenagers or young adults?

A: The medicine is officially established for use in post-menarchal females, which includes adult and adolescent women. Safety and efficacy have not been established, and the medicine is not to be used, in pre-menarchal females (children).


Q: Can taking Torgyn Duo affect the results of blood tests?

A: While systemic clindamycin use has been associated with changes in certain blood tests (such as transient neutropenia or abnormalities in liver function tests), these effects are generally associated with high systemic exposure, which is minimal with the topical ovule.


Q: Why is alcohol generally advised against when taking Torgyn Duo?

A: Alcohol consumption is strongly discouraged during treatment and for a specified period after the final dose. This is because the medicine contains an ingredient that can cause a disulfiram-like reaction when combined with alcohol, leading to symptoms like flushing, headache, nausea, and vomiting.


Q: Is Torgyn Duo used for nerve pain, or only for muscle/joint pain?

A: Torgyn Duo is indicated only for the localized treatment of mixed vaginal infections. It is not approved or intended for the treatment of any type of nerve, muscle, or joint pain.


Q: Does the time of day matter when taking Torgyn Duo?

A: Official administration instructions generally recommend using the ovule at bedtime. This timing is suggested to maximize the localized contact time of the active ingredients with the vaginal tissue and promote retention of the medicine at the affected site.


Q: What should I do if a minor side effect from Torgyn Duo doesn't go away?

A: Patient counseling information states that persistent or bothersome side effects, even minor ones like localized irritation, should be reviewed with a healthcare provider.


Q: How is Torgyn Duo thought to improve patient outcomes in comparison to its individual components?

A: The combination is designed to provide simultaneous, focused coverage against a broad range of susceptible bacterial and fungal pathogens. This dual-mechanism approach may offer a simplified management strategy and leverage a synergistic effect against mixed infections.


Q: What kind of studies support the claims made about Torgyn Duo?

A: The efficacy of Torgyn Duo is supported by clinical research, including Randomized Controlled Trials (RCTs) and comparative studies. These studies monitor both clinical endpoints, such as the resolution of patient symptoms, and microbiological endpoints, which track the status of the target pathogens.


Q: Is it normal to have a slight stomach upset when I start Torgyn Duo?

A: Gastrointestinal disturbances are listed in the regulatory safety documents as a system-organ class involved in adverse reactions. Any persistent or concerning gastrointestinal effects are advised to be reported to a healthcare provider.


Q: Can Torgyn Duo make you feel sleepy or affect driving ability?

A: Nervous system disorders are listed as a category of adverse reactions. While specific warnings about sleepiness or driving ability are not detailed in all regulatory documents, any noted effects on the nervous system, such as changes in alertness, should be reported to a healthcare professional.


Q: Can women who are planning to get pregnant safely use Torgyn Duo?

A: Official regulatory guidance states that use during established pregnancy is conditional and should only be administered if the medical benefit clearly outweighs the potential risks. Individuals actively planning conception are advised to review the use of this medicine with their healthcare provider.

How should Torgyn Duo be stored and disposed of?

Storage and Environmental Requirements

Official regulatory documents require Torgyn Duo ovules to be stored at a controlled room temperature of 25 C (77 F), with temperature excursions permitted only between 15 C and 30 C (59 F and 86 F). The product must be protected from excess heat and moisture. Storage in environments above 30 C is not permitted. To maintain product stability, the medicine must be kept in the container it came in and kept tightly closed.

Disposal and Child Safety

The medicine's regulatory label includes explicit instructions for child safety: the product must be stored out of the sight and reach of children. Unused or expired Torgyn Duo must be disposed of according to official procedures. This includes utilizing a medication take-back program or following specific guidance for preparing the product for household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Torgyn Duo found in:

A-Z Index: